专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08034815B2 Compounds and method for treatment of cancer 有权
标题翻译：化合物和治疗癌症的方法
公开(公告)号：US08034815B2
公开(公告)日：2011-10-11
申请号：US12013079
申请日：2008-01-11
申请人： Wayne R. Danter , Martyn Brown , Franck LePifre
发明人： Wayne R. Danter , Martyn Brown , Franck LePifre
IPC分类号： A61K31/497 , A61K31/535 , C07D417/12 , C07D401/12 , C07D403/12
CPC分类号： C07D401/12 , C07D471/04
摘要： The present invention is directed to a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.
摘要翻译：本发明涉及式I化合物：和/或药学上可接受的盐，水合物，溶剂化物，互变异构体，旋光异构体或其组合，包含缩氨基硫脲的组合物，其施用方法及其用途治疗癌症。

2. 发明授权

US08420643B2 Compounds and method for treatment of cancer 有权
标题翻译：化合物和治疗癌症的方法
公开(公告)号：US08420643B2
公开(公告)日：2013-04-16
申请号：US13310506
申请日：2011-12-02
申请人： Wayne R. Danter , Martyn Brown , Franck LePifre
发明人： Wayne R. Danter , Martyn Brown , Franck LePifre
IPC分类号： A61K31/535 , A61K31/497 , C07D403/12 , C07D417/12 , C07D401/12
CPC分类号： C07D401/12 , C07D471/04
摘要： The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.
摘要翻译：本发明涉及使用式I化合物和/或其药学上可接受的盐，水合物，溶剂化物，互变异构体，旋光异构体或其组合的方法，包含缩氨基硫脲的组合物，其施用方法，及其用途来治疗癌症。

3. 发明授权

US08367675B2 Compounds and method for treatment of cancer 有权
公开(公告)号：US08367675B2
公开(公告)日：2013-02-05
申请号：US13190230
申请日：2011-07-25
申请人： Wayne R. Danter , Martyn Brown , Franck LePifre
发明人： Wayne R. Danter , Martyn Brown , Franck LePifre
IPC分类号： A61K31/497 , A61K31/535
CPC分类号： C07D401/12 , C07D471/04
摘要： The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.

4. 发明申请

US20120077820A1 COMPOUNDS AND METHOD FOR TREATMENT OF CANCER 有权
标题翻译：化合物和治疗癌症的方法
公开(公告)号：US20120077820A1
公开(公告)日：2012-03-29
申请号：US13310506
申请日：2011-12-02
申请人： Wayne R. Danter , Martyn Brown , Franck LePifre
发明人： Wayne R. Danter , Martyn Brown , Franck LePifre
IPC分类号： A61K31/496 , A61P35/00 , A61P35/02 , C07D401/14
CPC分类号： C07D401/12 , C07D471/04
摘要： The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.
摘要翻译：本发明涉及使用式I化合物和/或其药学上可接受的盐，水合物，溶剂化物，互变异构体，旋光异构体或其组合的方法，包含缩氨基硫脲的组合物，其施用方法，及其用途来治疗癌症。

5. 发明申请

US20080171744A1 COMPOUNDS AND METHOD FOR TREATMENT OF CANCER 有权
标题翻译：化合物和治疗癌症的方法
公开(公告)号：US20080171744A1
公开(公告)日：2008-07-17
申请号：US12013079
申请日：2008-01-11
申请人： Wayne R. Danter , Martyn Brown , Franck LePifre
发明人： Wayne R. Danter , Martyn Brown , Franck LePifre
IPC分类号： A61K31/5375 , A61P35/00 , C07D401/14 , C07D415/00 , A61K31/497
CPC分类号： C07D401/12 , C07D471/04
摘要： The present invention is directed to a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.
摘要翻译：本发明涉及式I化合物：和/或药学上可接受的盐，水合物，溶剂化物，互变异构体，旋光异构体或其组合，包含缩氨基硫脲的组合物，其施用方法及其用途治疗癌症。

6. 发明申请

US20110281887A1 COMPOUNDS AND METHOD FOR TREATMENT OF CANCER 有权
标题翻译：化合物和治疗癌症的方法
公开(公告)号：US20110281887A1
公开(公告)日：2011-11-17
申请号：US13190230
申请日：2011-07-25
申请人： Wayne R. Danter , Martyn Brown , Franck LePifre
发明人： Wayne R. Danter , Martyn Brown , Franck LePifre
IPC分类号： A61K31/497 , A61P35/00 , A61P35/02 , A61K31/496
CPC分类号： C07D401/12 , C07D471/04
摘要： The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.
摘要翻译：本发明涉及使用式I化合物和/或其药学上可接受的盐，水合物，溶剂化物，互变异构体，旋光异构体或其组合的方法，包含缩氨基硫脲的组合物，其施用方法，及其用途来治疗癌症。

7. 发明申请

US20090298855A1 Protein Tyrosine Kinase Inhibitors 有权
标题翻译：蛋白酪氨酸激酶抑制剂
公开(公告)号：US20090298855A1
公开(公告)日：2009-12-03
申请号：US12510862
申请日：2009-07-28
申请人： Wayne R. Danter , Martyn Brown , George Ma , Ghenadie Rusu , Jianhua Zhong , Natalie Lazarowych , Stephen Houldsworth
发明人： Wayne R. Danter , Martyn Brown , George Ma , Ghenadie Rusu , Jianhua Zhong , Natalie Lazarowych , Stephen Houldsworth
IPC分类号： A61K31/506 , C07D401/12 , A61K31/4545 , A61P35/00
CPC分类号： C07D401/14
摘要： The present invention relates to compounds of the Formula I, the pharmaceutically acceptable salts and stereoisomers thereof, which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions in mammals: wherein n is an integer, preferably n is 1; wherein R1 and R2 are independently selected from the group consisting of:
摘要翻译：本发明涉及抑制，调节和/或调节酪氨酸激酶信号转导的式I化合物及其药学上可接受的盐和立体异构体，以及使用它们治疗酪氨酸激酶依赖性疾病的方法和哺乳动物的条件：其中n为整数，优选n为1; 其中R1和R2独立地选自：

8. 发明授权

US08252800B2 Protein tyrosine kinase inhibitors 有权
标题翻译：蛋白酪氨酸激酶抑制剂
公开(公告)号：US08252800B2
公开(公告)日：2012-08-28
申请号：US12510862
申请日：2009-07-28
申请人： Wayne R. Danter , Martyn Brown , George Ma , Ghenadie Rusu , Jianhua Zhong , Natalie Lazarowych , Stephen Houldsworth
发明人： Wayne R. Danter , Martyn Brown , George Ma , Ghenadie Rusu , Jianhua Zhong , Natalie Lazarowych , Stephen Houldsworth
IPC分类号： C07D401/14 , A61K31/506
CPC分类号： C07D401/14
摘要： The present invention relates to compounds of the Formula I, the pharmaceutically acceptable salts and stereoisomers thereof, which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions in mammals: wherein n is an integer, preferably n is 1; wherein R1 and R2 are independently selected from the group consisting of:
摘要翻译：本发明涉及抑制，调节和/或调节酪氨酸激酶信号转导的式I化合物及其药学上可接受的盐和立体异构体，以及使用它们治疗酪氨酸激酶依赖性疾病的方法和哺乳动物的条件：其中n为整数，优选n为1; 其中R1和R2独立地选自：

9. 发明授权

US07585866B2 Protein tyrosine kinase inhibitors 有权
标题翻译：蛋白酪氨酸激酶抑制剂
公开(公告)号：US07585866B2
公开(公告)日：2009-09-08
申请号：US10522944
申请日：2003-07-31
申请人： Wayne R. Danter , Martyn Brown , George Ma , Ghenadie Rusu , Jianhua Zhong , Natalie Lazarowych , Stephen Houldsworth
发明人： Wayne R. Danter , Martyn Brown , George Ma , Ghenadie Rusu , Jianhua Zhong , Natalie Lazarowych , Stephen Houldsworth
IPC分类号： C07D401/14 , A61K31/506
CPC分类号： C07D401/14
摘要： The present invention relates to compounds of the Formula I, the pharmaceutically acceptable salts and stereoisomers thereof, which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions in mammals: wherein n is an integer, preferably n is 1; wherein R1 and R2 are independently selected from the group consisting of:
摘要翻译：本发明涉及抑制，调节和/或调节酪氨酸激酶信号转导的式I化合物及其药学上可接受的盐和立体异构体，以及使用它们治疗酪氨酸激酶依赖性疾病的方法和哺乳动物的条件：其中n为整数，优选n为1; 其中R1和R2独立地选自：

10. 发明授权

US07629347B2 Protein tyrosine kinase inhibitors 有权
标题翻译：蛋白酪氨酸激酶抑制剂
公开(公告)号：US07629347B2
公开(公告)日：2009-12-08
申请号：US10531107
申请日：2003-10-09
申请人： Wayne R. Danter , George Ma , Natalie Lazarowych , Stephen Houldsworth , Martyn Brown , Ghenadie Rusu , Jianhua Zhong
发明人： Wayne R. Danter , George Ma , Natalie Lazarowych , Stephen Houldsworth , Martyn Brown , Ghenadie Rusu , Jianhua Zhong
IPC分类号： C07D401/14 , A61K31/506
CPC分类号： C07D401/14 , A61K31/506
摘要： The present invention relates to uses of the compounds of Formula I as well as pharmaceutically acceptable salts and stereoisomers thereof in methods to treat a variety of tumors in mammals involving abnormal tyrosine kinase signaling, the compounds represented as: wherein R1 and R2 are independently selected from the group consisting of H; alkyl; alkenyl; alkynyl; halogen; aryl; heteroaryl containing N, O, or S; the aryl and heteroaryl may be further substituted with halogen, an alkyl, alkenyl, and alkynyl; NZ1Z2, wherein Z1 and Z2 are independently selected from the group consisting of H and alkyl; and (CO)Y wherein Y is selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, heteroaryl containing N, O, or S, and the aryl and heteroaryl may be further substituted with halogen, alkyl, alkenyl, and alkynyl; with the proviso that when R1 is hydrogen, R2 is a group other than hydrogen.
摘要翻译：本发明涉及式I化合物及其药学上可接受的盐和立体异构体在治疗涉及异常酪氨酸激酶信号传导的哺乳动物中的各种肿瘤的方法中的用途，所述化合物表示为：其中R1和R2独立地选自由H组成的组; 烷基; 烯基; 炔基; 卤素; 芳基; 含有N，O或S的杂芳基; 芳基和杂芳基可以进一步被卤素，烷基，烯基和炔基取代; NZ1Z2，其中Z1和Z2独立地选自H和烷基; 和（CO）Y，其中Y选自H，烷基，烯基，炔基，芳基，含有N，O或S的杂芳基，芳基和杂芳基可以进一步被卤素，烷基，烯基和炔基; 条件是当R 1是氢时，R 2是不同于氢的基团。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式